获得性MET-DSTN融合介导的肺腺癌对EGFR-TKIs耐药及对克唑替尼联合吉非替尼的反应：一例报告 - Suppr

Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.

作者信息

Li Yalun, Wang Ke, Tian Panwen, Li Weimin

机构信息

Department of Respiratory and Critical Care Medicine, Lung Cancer Treatment Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

Department of Respiratory and Critical Care Medicine, Lung Cancer Treatment Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China..

出版信息

Clin Lung Cancer. 2022 Jan;23(1):e83-e86. doi: 10.1016/j.cllc.2021.10.006. Epub 2021 Oct 25.

DOI:10.1016/j.cllc.2021.10.006

PMID:34802880

Abstract

摘要

相似文献

Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.获得性MET-DSTN融合介导的肺腺癌对EGFR-TKIs耐药及对克唑替尼联合吉非替尼的反应：一例报告

Clin Lung Cancer. 2022 Jan;23(1):e83-e86. doi: 10.1016/j.cllc.2021.10.006. Epub 2021 Oct 25.

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.获得性 MET D1228N 突变介导 ROS1 融合肺腺癌对克唑替尼的耐药：一例报告。

Oncologist. 2021 Mar;26(3):178-181. doi: 10.1002/onco.13545. Epub 2020 Oct 28.

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.克唑替尼联合或不联合 EGFR-TKI 治疗 EGFR 突变型 NSCLC 患者 EGFR-TKI 治疗失败后获得性 MET 扩增：一项多中心回顾性研究。

J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.

Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.吉非替尼耐药后，克唑替尼与吉非替尼联合用于伴有软脑膜转移且MET扩增的晚期肺腺癌：一例报告及文献综述

Clin Lung Cancer. 2019 May;20(3):e251-e255. doi: 10.1016/j.cllc.2018.12.004. Epub 2018 Dec 19.

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.携带有间充质-上皮转化因子外显子 14 跳跃突变的肺腺癌患者对克唑替尼和卡博替尼的反应：一例报告。

Medicine (Baltimore). 2021 Jan 29;100(4):e24300. doi: 10.1097/MD.0000000000024300.

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.具有 EGFR 突变和 ALK 重排的非小细胞肺癌的临床处理：EGFR 酪氨酸激酶抑制剂和克唑替尼的疗效。

Target Oncol. 2019 Apr;14(2):169-178. doi: 10.1007/s11523-019-00628-6.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.特泊替尼联合吉非替尼治疗既往 EGFR 抑制剂治疗后出现 MET 过表达或扩增的 EGFR 突变型非小细胞肺癌患者：一项开放标签、Ib/II 期、多中心、随机试验（INSIGHT 研究）。

Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29.

A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.一例HLA-DRB1-MET重排的肺腺癌对克唑替尼快速反应的病例

Clin Lung Cancer. 2021 May;22(3):e298-e300. doi: 10.1016/j.cllc.2020.05.005. Epub 2020 Jun 12.

Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.携带有 MET 扩增的 EGFR 突变型肺癌患者使用吉非替尼联合克唑替尼治疗获得成功。

Curr Probl Cancer. 2021 Oct;45(5):100702. doi: 10.1016/j.currproblcancer.2020.100702. Epub 2021 Jan 9.

[Management of a patient with a double EGFR and MET anomaly by combined treatment].[通过联合治疗对一名存在双EGFR和MET异常的患者进行管理]

Rev Mal Respir. 2020 Jun;37(6):488-491. doi: 10.1016/j.rmr.2020.03.007. Epub 2020 May 16.

引用本文的文献

MET fusions are targetable genomic variants in the treatment of advanced malignancies.MET 融合是晚期恶性肿瘤治疗中可靶向的基因组变异。

Cell Commun Signal. 2024 Jan 9;22(1):20. doi: 10.1186/s12964-023-01454-0.

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.Tepotinib 联合吉非替尼对比化疗用于因 MET 扩增导致 EGFR 抑制剂耐药的 EGFR 突变 NSCLC 的随机试验：INSIGHT 最终分析。

Clin Cancer Res. 2023 May 15;29(10):1879-1886. doi: 10.1158/1078-0432.CCR-22-3318.

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.鉴定肺癌中 MET 融合作为对 MET 抑制剂敏感的新型治疗靶点。

J Transl Med. 2023 Feb 25;21(1):150. doi: 10.1186/s12967-023-03999-7.

Case report: Salvage capmatinib therapy in fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin.病例报告：在对替雷利珠单抗维妥昔单抗耐药的融合阳性肺腺癌中使用卡马替尼进行挽救治疗。

Front Oncol. 2022 Aug 11;12:919123. doi: 10.3389/fonc.2022.919123. eCollection 2022.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献